Denufosol tetrasodium
CAS: 318250-11-2
Ref. 3D-ND45968
1mg | 1,096.00 € | ||
2mg | 2,068.00 € | ||
5mg | 3,318.00 € | ||
10mg | 5,401.00 € | ||
500µg | 779.00 € |
Product Information
- 2'-Deoxycytidine P'''-5'-ester with uridine 5'-(pentahydrogen tetraphosphate) sodium saltUridine 5'-(pentahydrogen tetraphosphate)
- P'5'-ester 2'-deoxycytidineINS 37217[[(3S,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyp
- dCp4U
- Ins-37217
- Uridine 5'-(pentahydrogen tetraphosphate) P'''--5'-ester with 2'-deoxycytidine tetrasodium salt
- tetrasodium [[[[(3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate
- tetrasodium [[[[(2R,3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-oxido-phosphoryl]oxy-oxido-phosphoryl]oxy-oxido-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate
A P2Y2 receptor agonist that has been studied in cystic fibrosis and retinal diseases such as retinal detachment. Denufosol was studied as an inhaled drug for cystic fibrosis, due to its ability to activate an alternative chloride channel and avoiding the defective CFTR chloride channel. This enhances hydration of the lung mucosa and improves mucociliary clearance. The drug did not progress from phase III clinical trials. Denufosol resulted in subretinal fluid reabsorption in in vivo model of retinal detachment.
Chemical properties
Technical inquiry about: 3D-ND45968 Denufosol tetrasodium
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.